Shanghai Pharmaceuticals (02607.HK) terminates cooperation agreement with Guizhou Seno Bio-Technology Co., Ltd.

Intelligence Finance and Economics APP News, Shanghai Pharmaceuticals (02607.HK) announced that on October 8, 2021, Shanghai Pharmaceuticals Group Co., Ltd. (hereinafter referred to as "Shanghai Pharmaceuticals" or "the Company") wholly-owned subsidiary Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Shangyao Xinyi") signed a "Production, Sales and Development Cooperation Agreement" for the new acid inhibitor X842 project (hereinafter referred to as "X842") with Guizhou Senvers Biotechnology Co., Ltd. (hereinafter referred to as "Guizhou Senvers") and wholly-owned subsidiary Jiangsu Tairui Senvers Biomedical Technology Co., Ltd. (hereinafter referred to as "Jiangsu Senvers"). Shangyao Xinyi has obtained the exclusive commissioned production and industrial sales rights for X842 active pharmaceutical ingredients and formulations in the China region (including Hong Kong, Macau, and Taiwan) for all indications.